Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

April 28, 2021 at 16:30 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following virtual investor conferences:

B. Riley Neuroscience Conference

Date and Time: Thursday, April 29, 9:00 a.m. ET
Speakers: Scott Braunstein, M.D., Chief Executive Officer, and Joe Hulihan, M.D., Chief Medical Officer
Webcast Link: https://www.webcaster4.com/Webcast/Page/2433/41077

7th Annual Truist Securities Life Sciences Summit

Date and Time: Tuesday, May 4, 11:20 a.m. ET
Speakers: Scott Braunstein, M.D., Chief Executive Officer, and Joe Hulihan, M.D., Chief Medical Officer
Webcast Link: https://kvgo.com/life-sciences-summit/marinus-pharmaceuticals-may-2021

Oppenheimer Rare & Orphan Disease Summit

Date and Time: Available on demand starting Friday, May 21, 8:00 a.m. ET
Speakers: Scott Braunstein, M.D., Chief Executive Officer, and Joe Hulihan, M.D., Chief Medical Officer
Webcast Link: https://wsw.com/webcast/oppenheimer12/mrns/2811616

UBS Global Healthcare Virtual Conference

Date and Time: Monday, May 24, 8:00 a.m. ET
Speakers: Scott Braunstein, M.D., Chief Executive Officer, and Steven Pfanstiel, Chief Financial Officer

All of the above webcasts may be accessed through the Events & Presentations page of the Investors & Media section of the Marinus website, www.marinuspharma.com.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABA_A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, is conducting a Phase 2 trial in tuberous sclerosis complex, and has recently disclosed top line results from its Phase 2 proof-of-concept trial in PCDH19-related epilepsy. The company has initiated a Phase 3 trial in refractory status epilepticus. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428006117/en/

Contacts

Sasha Damouni Ellis

Vice President, Investor Relations & Corporate Communications

Marinus Pharmaceuticals, Inc.

484-253-6792

sdamouni@marinuspharma.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article